ABVC BioPharma, Inc.
ABVC
$0.96
-$0.10-9.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -50.84% | -29.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -50.43% | -28.37% | |||
| Operating Income | 50.43% | 47.43% | |||
| Income Before Tax | 52.04% | 55.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 52.04% | 55.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -43.33% | -48.02% | |||
| Net Income | 52.77% | 56.21% | |||
| EBIT | 50.43% | 47.43% | |||
| EBITDA | 50.66% | 47.52% | |||
| EPS Basic | 53.83% | 57.46% | |||
| Normalized Basic EPS | 55.06% | 45.15% | |||
| EPS Diluted | 53.83% | 58.33% | |||
| Normalized Diluted EPS | 55.06% | 45.15% | |||
| Average Basic Shares Outstanding | 2.40% | 2.89% | |||
| Average Diluted Shares Outstanding | 2.40% | 2.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||